Skip to main content
. Author manuscript; available in PMC: 2022 Sep 21.
Published in final edited form as: J Control Release. 2022 Aug 9;349:929–939. doi: 10.1016/j.jconrel.2022.07.042

Fig. 1. The self-assembly process, antitumor immune responses, and endocytotic pathway evaluation of Camptothesome.

Fig. 1.

(a) Camptothesome formed by Sphingomyelin (SM), SM-CSS-CPT conjugate[22], DSPE-PEG2K and cholesterol. (b) The antitumor immunity triggered by Camptothesome through eliciting immunogenic cell death (ICD). (c,d) The effects of endocytotic inhibitors on the cellular uptake of Cy5.5-labeled Camptothesome in CT26 cells through measuring the Cy5.5 intensity using flow cytometry. CT26 cells were pretreated with various endocytotic inhibitors for 0.5 h then incubated with Cy5.5/Camptothesome (50 μg CPT/mL) in the presence of the inhibitors for additional 2 h. (c) Representative flow cytometry histograms of Cy5.5/Camptothesome. (d) Cellular uptake percentage rate of Cy5.5/Camptothesome analyzed by flow cytometry. Data in d is expressed as mean ± s.d. (n = 3). Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparisons test. ****P < 0.0001 vs 5% Dextrose.